NOBO Deodorant vs Placebo Body Odor Control Proof-of-Concept Study
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov has registered a proof-of-concept study (NCT07547761) evaluating the efficacy of NOBO, a yeast-based fermentate aqueous deodorant spray, against a placebo in controlling axillary (body) odor in healthy adults aged 18–70. The study will assess self-perceived odor and skin microbiome via qPCR at multiple time points using a split-axilla design — one axilla treated with NOBO, the contralateral axilla with placebo. Participants will also self-assess skin irritation. No regulatory compliance obligations or enforcement actions are associated with this trial registration.
“The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentate designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a new clinical trial on ClinicalTrials.gov. The trial evaluates NOBO aqueous deodorant spray against a placebo aqueous deodorant spray for control of axillary body odor in healthy male and female adults aged 18–70. Participants will self-assess odor and irritation, with third-party odor evaluation via cotton round sampling and skin microbiome analysis via qPCR.
Healthcare providers and clinical investigators conducting or referring patients to odor or dermatology studies should be aware of this proof-of-concept trial as a potential recruitment or citation opportunity. The trial imposes no compliance obligations on non-participating entities.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOBO Body Odor Control Efficacy Proof-of-Concept Study #1
N/A NCT07547761 Kind: NA Apr 23, 2026
Abstract
The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentate designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is:
Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla to the placebo axilla to see if there is a difference in self-perceived odor and microbiome.
Participants will:
- be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)
- self assess body odor
- sample axilla with cotton round for 3rd party odor assessment
- sample axilla with a swab for skin microbiome analysis via qPCR
- self assess skin irritation
Conditions: Body Odor
Interventions: NOBO Aqueous Deodorant, Placebo Aqueous Deodorant
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.